Assembly Biosciences Inc — Quarterly Cash Flow (NASDAQ:ASMB) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets 119.17 M99.02 M80.78 M240 M257.59 M Total liabilities 85.81 M71.88 M62.68 M57.3 M50.84 M Total equity 33.36 M27.13 M18.1 M182.69 M206.75 M Total liabilities & shareholders' equities 119.17 M99.02 M80.78 M240 M257.59 M Total debt ————— Net debt —————

News

Assembly Biosciences: 'Buy' On HPI Program Opt-In And HDV Candidate Development (ASMB)

Assembly Biosciences (ASMB) Q4 Earnings and Revenues Top Estimates

Metagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue Estimates

Personalis (PSNL) Reports Q4 Loss, Misses Revenue Estimates

Supernus Pharmaceuticals (SUPN) Surpasses Q4 Earnings and Revenue Estimates

GILD Exercises Option to License Assembly Bio's Herpes Programs

Gilead Sciences Bets On Weekly Pill To Tackle Genital Herpes - Assembly Biosciences (NASDAQ:ASMB), Gilead Sciences (NASDAQ:GILD)

Gilead exercises option for Assembly Bio’s herpes treatment programs

Jefferies raises Assembly Biosciences stock price target to $62 on HSV data

Assembly Biosciences, Inc. (ASMB) Discusses Positive Interim Results for ABI-1179 and ABI-5366 in Recurrent Genital Herpes Phase 1b Studies Transcript

Assembly Biosciences, Inc. (ASMB) Discusses Positive Interim Results for ABI-1179 and ABI-5366 in Recurrent Genital Herpes Phase 1b Studies - Slideshow (NASDAQ:ASMB) 2025-12-08

Assembly Biosciences stock rises after promising HSV drug results